Marketresearchnews

Tuesday, 15 December 2020

Blood Transfusion Diagnostics Market to Witness an Outstanding Growth by 2023

Market Research Future published a Half Cooked Research Report on “Global Blood Transfusion Diagnostics Market Research Report-Forecast to 2027” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027.

Ortho Clinical Diagnostics (U.S), Immucor (U.S), Beckman Coulter (U.S), Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens (Germany), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany), DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).are some of the prominent players at the forefront of competition in the global Blood Transfusion Diagnostics market and top seven players are profiled in MRFR Analysis.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1126

Global Blood Transfusion Diagnostics Market – Overview

Blood transfusion is an essential part of providing healthcare services to the patients. Blood and blood products like RBC’s, WBC’s, platelets and others are transfused from one person to another. This requires screening tests which are vital before conducting blood transfusion. Strict regulation governing the use and transfer of blood, increasing awareness regarding blood transfusion and automation of blood banks drive the growth of this market. Furthermore, increasing demand for diagnostic and treatment devices in developed and developing countries further influence the growth of the market. However, the growth of the market is restrained by various factors such as risk involved in transmission of infectious disease from one person to another without carrying out screening procedure.

Global Blood Transfusion Diagnostics Market – Competitive Analysis

There is a significant increase in the number of the company offering blood transfusion diagnostics. Some major companies are trying to focus on new and advanced tests & products to gain the market. Whereas, some are has used the technique of acquisition and collaboration to gain the blood transfusion diseases market.

Hoffmann-La Roche AG:

August, 2015: F. Hoffmann-La Roche AG acquired GeneWEAVE to strengthen offerings in microbiology diagnostics. Roche will pay GeneWEAVE shareholders USD 190 million upfront and up to USD 235 million in contingent product related milestones
February 2015 : F. Hoffmann-La Roche AG announced the collaboration with BioMed X for the development of Nanomaterial-Based Biosensors for Near-Patient Testing
September 2014: F. Hoffmann-La Roche AG launched Elecsys anti-Müllerian Hormone (AMH) fertility test for assessment of ovarian reserve for pregnancy

Abbott:

June, 2017: Alere shareholders approve amended merger with Abbott. This merger will further strengthen the global presence of the company.
August, 2016: Abbott announced the introduction of its new “Alinity”, a family of next generation systems across immunoassay, clinical chemistry, point of care, haematology, blood and plasma screening and molecular diagnostics.
April, 2016: The company received FDA approval for its companion diagnostics “Vysis CLL FISH probe kit” in Leukemia. The kit is used to detect the 17p deletion in chronic lymphocytic leukemia patients, the target population of a new drug from AbbVie.
April, 2016: Abbott received FDA approval for its companion diagnostics “Vysis CLL FISH probe kit” in Leukemia. The kit is used to detect the 17p deletion in chronic lymphocytic leukemia patients, the target population of a new drug from AbbVie.

Bio-Rad Laboratories, Inc.:

July 2017: Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products launched Amplichek I quality control for the testing of infectious diseases.

Global Blood Transfusion Diagnostics Market – Regional Analysis

Globally, Americas account for the largest market share in blood transfusion diagnostics market consists of two regions namely North America and South America. Increasing in number of blood banks, adoption of automation in blood banks, awareness programs in school & medical institutes and demand of safe and reliable technology for blood transfusion drive this market in North America. Increasing adoption of Nucleic Acid Amplification for diagnosis of blood and blood products also contribute to the growth of this market in North America. United States is the biggest market place worldwide contributing 46% of total blood transfusion diagnostics market. Ortho-Clinical Diagnostic is the largest transfusion diagnostic equipment and solution provider with estimated market share of 7 to 8%. Medical institutes conduct lecture and conference on safe blood transfusion for medical students and also for patients. Europe blood transfusion diagnostics market has observed stable growth owing to increasing demand for advanced diagnostic products. Asia-Pacific is fastest growing market region for this market due to presence of huge patient pool, and huge opportunity for the market growth. The Middle East and Africa holds the least share in the market due to lack of awareness among the people and limited development of medical sector.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/blood-transfusion-diagnostics-market-1126

Global Botulism Illness Market Research Report 2020 Analysis and Forecast to 2023

Market Research Future adds the “Botulism Illness Market Research Report – Forecast to 2023” report to their unique collection. Botulism Illness Market Is Expected To Grow At A CAGR Of 5.9% During Forecasted Period 2017-2023.

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Botulism Illness Market Research Report – Forecast to 2023” Gives industry size, top players and worldwide demand

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/822

Study objectives global botulism illness market

To provide detailed information about drivers and factors restraining the market growth.
To provide the market growth map over the forecasted period 2017-2023
To provide detailed analysis of the market structure along with forecast for the next seven years of various segments and sub-segments of the global botulism illness
To provide the graphs and analyze the market on various factors like- Price Analysis, Supply Chain Analysis, Porters Five Force Analysis etc.
To provide the trends and opportunities in global botulism illness
To provide historical and forecast revenue of the market segments and sub-segments with respect to main countries
To provide the overview of key players and their strategic profiles in the market and drawing a competitive landscape for the market

Intended Audience

Pharmaceutical companies
Research and Development (R&D) companies
Independent research laboratories
Market research and consulting service providers
Medical research laboratories
Academic medical institutes and universities

Market scenario:

Botulism illness is one of the rare and fatal paralytic disorders caused by neurotoxins produced by a bacteria Clostridium botulinum. Weakness, feeling tired, trouble in speaking and fever are some of the major symptoms of the disease. Botulism can be spread several different ways and is mainly caused due to food, water and neighbouring environment. The major driving factor for the growth of global botulism illness market are increasing prevalence of botulism, lack of hygiene in certain regions of the world, availability of efficient solutions for botulism and increase in R&D practices. Increasing awareness among the people also contribute to the growth of the market. However, high cost of R&D and long approval time for the drug are some of the hurdles expected to hinder the growth of botulism illness market

Botulism Illness Market share Is Expected To Grow At A CAGR Of 5.9% During Forecasted Period 2017-2023.

Segmentation

Global botulism illness market is segmented on the basis of type, into botulinum type A and botulinum type B. On the basis of drug type, the market is segmented into antibiotics, antitoxins and others. Antitoxin are further sub segmented into trivalent antitoxin and heptavalent botulinium antitoxin and on the basis end users, the market is segmented into hospital, clinics and other

Regional analysis

On regional basis, America accounts for the largest market of global botulism illness followed by Europe. Well-developed healthcare sector, increasing healthcare expenditure and increasing awareness among the people are the major factors for the growth of the market in America. Asia Pacific is the fastest growing region for the market due to rapid development in the economies and increasing healthcare expenditure.

Key players for global botulism illness market

Allergan Inc. (Ireland), XOMA Corporation (US), Pfizer Inc. (US), AlphaVax, Inc (US), Microbiotix, Inc (US), Molecular Targeting Technologies, Inc (US), Ipsen Technologies Pvt. Ltd (France), Galderma S. A. (Switzerland), Canbex Therapeutics Ltd (US), Azidus (US)

The report for global botulism illness market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/global-botulism-illness-market-822

Atrial Fibrillation Market: Detailed Segmentation and Forecast 2023

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Atrial Fibrillation Market Analysis – Forecast Report Till 2023” Gives industry size, top players and worldwide demand

Industry Overview

The worldwide atrial fibrillation market is predicted to grow at a double digit CAGR over the forecast period (2017 to 2023). Atrial fibrillation, also denoted as AF, is an irregular or fast heart rhythm. It raises the dangers of chest pain, heart strokes, congestive heart failure, or cardiac discomfort. The typical indications of AF are dizziness, confusion, fainting, or tiredness.

AF cases within the elderly population, preference for catheter ablation, and escalating technological developments propel the AF market. Atrial fibrillation is a majorly common arrhythmia that results in disturbed cardiac rhythms. In the last twenty years, a higher existence of AF incidences has been witnessed around the globe. The ‘American Heart Association’ stated that about 34 million people were afflicted with AF globally in 2013.

Also, the United States observes approximately 200, 000 to 400, 000 fresh cases every year. Rising AF cases have been the key contributor of this industry. Moreover; diabetics, high-blood pressure patients, and obese people have developed cardiac problems, eventually propelling the industry. Rheumatic fever incidences have seen a rise, driving the atrial fibrillation market from 2017 to 2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5661

Scientists and field experts have been collaborating to come up with innovative technologies for the premature diagnosis of AF. They have also been trying to offer better treatments to AF patients. Both these factors have generated higher demand for AF devices, furthering industry growth. On the other hand, increase in therapeutic expenses and scarcity of proficient doctors hamper the market.

According to a study by ‘Market Research Future’ (MRFR), the global AF market is set to experience decent expansion in the forecast period. Various lifestyle illnesses, poor eating habits, and sedentary occupations may also cause a surge in cardiac issues, leading to some of the AF incidences. All these factors could further contribute to the growth of this industry. Another hindrance for the market comprises the inclination towards pharmaceutical drugs over AF therapeutics.

Classification/Segmentation

The global atrial fibrillation market is divided on the basis of products, end-users, and geographical regions. By products, the industry is fragmented into non-surgical and surgical. The end users consist of cardio centers, big hospitals, and heart specialty care enterprises. Geographical regions into which the market is split, comprise Americas, Europe, Asia Pacific, and the Middle East and Africa.

Catheter ablation, a sub-segment of surgical products, is typically adopted for managing & treating cardiac arrhythmias. It is normally advised for the management of atrial fibrillation when patients can neither tolerate nor be given anti-coagulation drugs. Hence, catheter ablation occupied major shares in 2015. It is reported to be the most rapidly growing sub-segment in the near future.

Modern heart specialty and cardiac centers should witness the maximum adoption of AF devices. In view of geographies, Americas maintains supremacy over the market and would do the same in the forecast period. The usage of high-tech products & services and improved medical infrastructure is accountable for the same. Mexican sellers and government have spent heavy capital on the AF industry.

Asia Pacific will grow at the fastest pace & be driven by its huge patient base and population. Additionally, its need for atrial fibrillation devices can increase owing to better medical infrastructure and high Chinese & Indian healthcare costs.

Worldwide Rivals and Innovative Trends

Some of the well-established players operating in the global market are Biosense Webster, Carima, Agricore, Medtronic, and St. Jude Medical. They focus on new therapies for gaining wide recognition and edge over one another.

Catheter ablation has been further modified to suit patient-needs and offer cutting-edge therapies for AF patients. Majority of the patients across developed nations are treated with catheter pulmonary vein ablation. Such patients do not recover from medicines and have symptomatic AF.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/atrial-fibrillation-market-5661

Stem Cell Assay Market – A market with high CAGR and return on investment by 2023

Market Insights:

Stem Cells have been acknowledged for their promising potential toward the development of various cutting-edge treatments for a number of diseases. As such, stem cell assays have a rapidly growing market. Stem cell assays are essentially the techniques used for analyzing living cells by various parameters which ultimately help determine the biochemical and cellular functioning of cells. This has immense promise in drug development activities. Market Research Future’s study of the market in its latest report has found that the global stem cell assay market size to register a highly optimistic outlook at a CAGR of 19.80% during the review period from 2017 to 2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5656

Stem cell assays are a promising part of the biotechnology field, which is growing at a rapid pace. The prevalence of chronic and several lifestyle diseases has compelled the growth of drug development activities in an effort to develop effective treatments. Diseases such as cancer and diabetes are soaring at high rates and the demand for better, efficient and more affordable treatments are driving the market toward growth. Healthcare expenditure across the globe is increasing, and advancement in biotechnology and other medical technologies is highly encouraging of market growth. Government support toward drug development for chronic diseases has increased stem cell assay research.

The market is held back by stringent government policies associated with approval of drugs as well as the high procedural cost of stem cell assays. Moreover, there is a lack of awareness regarding stem cell assays, and as a result, there is a dearth of skilled professionals which restrains market growth. However, growing healthcare activities and the increasing demand for treatment is likely to bring stem cell assays to the forefront and opportunities in the market are plentiful.

Market Segmentation:
Market structure is determined by its various significant sections which, in the report have been segmented on the basis of product, technology, assay, application, end-user, and region. Products in the market include flow cytometer, cell imaging systems, automated cell counter, kits, and others. The kits segment has been sub-segmented and includes umbilical cord stem cells, induced pluripotent stem cell kits, mesenchymal stem cell kits, and others.

The technology used in stem cell assays include microfluidics-based cell trap technologies, microfabricated assisted technology, and others

Assays in the market include cell identification assays, cell viability & toxicity assays, cell proliferation assays, cell apoptosis assays, and others.

Applications of stem cell assays can be found in orthopedic & musculoskeletal spine, dermatology, cardiovascular, central nervous system, and others.

End-users of stem cell assays include research organizations, academic institutes, biotechnology industries, academic institutes, and others.

Regional Analysis:
The Americas have captured the dominant share of the global market. The presence of North America in the region has had a significant impact on the regions market share possession. The rapid adoption of advanced medical technologies and the presence of a large patient population for various chronic diseases drive the Americas’ market. Moreover, the regions healthcare expenditure is rising, and there are several leading players present in the North American sub-market.

Meanwhile, growing at the fastest pace is the Asia Pacific regional market. Gradually increasing awareness regarding advanced medical biotechnology is strongly impacting growth in the region. Several emerging economies in the region have a rapidly growing biotechnology sector which fuelling market growth. Findings by the Indian Brand Equity Foundation suggest that the Indian subcontinent has 2% of the global biotechnology share. Several opportunities in the region are expected to lead to market proliferation.

Key Players:
Prominent players included in MRFR’s report are Cell Biolabs, Inc., Thermo Fisher Scientific, Hemogenix, Merck KGaA, Promega Corporation, GE Healthcare, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cellular Dynamics International Inc., STEMCELL Technologies Inc., and others

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/stem-cell-assay-market-5656

Dietary supplements Market Projected to Witness Vigorous Expansion by 2023

Market Scenario:

Historically, dietary supplements marketing has focused on promoting a specific specialty ingredient targeted at specific consumer health needs such as omega 3 for heart health, lutein for eye care and others. Personalized nutrition offers manufacturers, the chance to develop a relationship with consumers rather than a single transactional approach. Massive advancements in the dietary supplements preparation in the field of personalized nutrition along with the possibility of the superior drug formulation will uplift the U. S. dietary supplements in the age of personalized nutrition market. The economies of scale and scope resulting out of greater demand for dietary supplements is expected to significantly reduce the final price of the products thus benefiting the final consumers. Thus, increasing the prevalence of cancer and metabolic diseases will result in arise in the volume of the dietary supplements market.

Dietary supplements in an age of personalized nutrition is regarded as one of the most noteworthy changes in the healthcare sector because of its capability to provide improved drug delivery and better patient/individual treatment process. Massive advancements in the dietary supplements preparation in the field of personalized nutrition along with the possibility of the superior drug formulation will uplift the U. S. dietary supplements in the age of personalized nutrition market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5644

However, spurious and misbranded products and safety concerns of dietary supplements affect the growth of the U. S. dietary supplements in the age of personalized nutrition market negatively.

The U. S. dietary supplements in the age of personalized nutrition market is expected to grow at a CAGR of 7.95% during the forecast period 2017-2023.

Intended Audience:

Dietary Supplements Manufacturers
Research and Development (R&D) Companies
Market Research and Consulting Service Providers
Potential Investors

Segmentation

The U. S. dietary supplements in the age of personalized nutrition market is segmented by product category, application, gender, dosage form and end-user.

By the product category, it is segmented into vitamins, herbs & botanicals, sports supplements, meal supplements, minerals and other.

By the application, it is segmented into lifestyle diseases, inherited diseases, genetic predispositions and others.

By the gender, it is segmented into female and male. Female and male is further segmented into various age groups, namely, 55 + age group, 35-54 age group, 19-34 age group, and 0-18 age group.

By the dosage form, it is segmented into tablets, capsules, powder, liquids, soft gels and others.

By the end-users, it is segmented into hospitals & clinics, home care, and others.

Key Findings

The U. S. dietary supplements in the age of personalized nutrition market was USD 18,093.1 million in 2016
Vitamins is the largest segment, by product category which is projected to grow at a CAGR of 8.37% during the forecast period from 2017-2023
Female is the largest segment, by gender in S. and expected to grow at a rate of CAGR 8.45% during the forecast period
The tablets segment accounted for the largest market share with 28.3% for the U.S. dietary supplements in the age of personalized nutrition market by dosage and is expected grow with the CAGR of 8.44% for the forecast period.

Key Players

Some of the key players in this market are Nestlé Health Science, Danone Nutricia, Carlyle Group, Amway (Nutrilite), Archer Daniels Midland, Abbott Laboratories, Herbalife International, Amway, Danisco, Glanbia, Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Balchem Corporation, Natures Product Inc., Bactolac Pharmaceutical Inc. and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/u-s-dietary-supplements-market-5644

Fertility Services Market – Product Development is the best strategy for market position; Forecast till 2023

Market Highlights

Global Fertility Services Market size is expected to register a CAGR of 8.99% during the forecast period, with a market value of USD 44,136.91 Million by 2025. Fertility services are procedures or treatments used to cure genetic and fertility issues and assist with conception. These services include assisted reproductive technology (ART) methods and drugs that help infertile couples in planning a family.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6281

Segment Analysis

The Global Fertility Services Market has been segmented by underlying cause and treatment.

Based on the underlying cause, the fertility services market has been segregated into female infertility and male infertility.

The Global Fertility Services Market, based on the treatment, has been segmented into ART and infertility drugs. The ART treatment has been further segmented into in-vitro fertilization (IVF), frozen embryo replacement (FER), artificial insemination, and others.

Regional Analysis

The Global Fertility Services Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Europe is expected to dominate the global fertility services market. This can be attributed to the lower fertility rate in the region and increasing IVF tourism in Spain. For instance, according to the European Society of Human Reproduction and Embryology (ESHRE), Spain is the preferred destination by foreigners for reproductive procedures, representing almost 40% of European fertility tourism, which is estimated to rise in the future. Moreover, easy reimbursement policies and increasing obesity cases are also expected to drive market growth.

The Americas market for fertility services is estimated to be the second-largest during the review period. The high number of ART procedures in the US is expected to boost the growth of the regional market. For instance, as per the data mentioned by the Centers for Disease Control and Prevention, in 2017, nearly 284,385 ART cycles were performed at 448 clinics in the US. Additionally, late pregnancies and the high adoption rate of IVF treatment are further fueling the market growth.

Asia-Pacific is estimated to be the fastest-growing market owing to the declining fertility rates in the region. According to the data suggested by the World Bank, the fertility rate in Japan decreased at a rate of 1.6 in 2016. Moreover, fertility disorders followed by favorable reimbursement scenario is also positively affecting the market growth.

The market in the Middle East & Africa is expected to witness steady growth due to the reduced ovarian reserve in women in the Middle Eastern countries.

Key Findings of the Study

The Global Fertility Services Market is estimated to reach USD 44,136.91 Million by 2025 at a CAGR of 8.99% during the assessment period
Europe accounted for the largest share of the global fertility services market due to the low fertility rate and increasing obesity rate
Based on the underlying cause, the female infertility segment accounted for the largest market share of 5% in 2018
Based on treatment type, the Assisted Reproductive Technology (ART) segment accounted for the largest market share of 21% in 2018

Key Players

MRFR recognizes the following companies as the Key Players in the Global Fertility Services Market— Merck KGaA (Germany), CooperSurgical, Inc. (US), Care Fertility (UK), Ferring B.V. (Switzerland), INVO Bioscience (US), Vitrolife (Sweden), Monash IVF Group (Australia), Cook (US), FUJIFILM Irvine Scientific (US), and Kitazato Corporation (Japan).

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/fertility-services-market-6281

Nurse Call System 2020 Global Market Key Players, Analysis and Forecast to 2023

Nurse Call System Market Overview

Global nurse call system market is growing pervasively. The market is witnessing furthering prominence due to the increased need for remote care during the COVID 19 Pandemic. Growing geriatric population, alongside the vast patient population suffering from myriads of chronic diseases & disorders, creates a huge demand for advanced medical infrastructures such as assisted living centers. Also, the need for effective nurse call systems to run hospital operations smoothly, fuels market growth.

Besides, the increased demand for active tracking of patients, especially in assisted living, old-age homes, and ambulatory service centers, accelerates the growth of the market to furthered height. All these factors cumulatively allow the market to garner significant traction across the globe. According to Market Research Future (MRFR), the global nurse call system market is estimated to register 9.5 % CAGR throughout the projected period (2017-2023).

Get a FREE Sample (Including COVID19 Impact Analysis, Full TOC, Tables and Figures) of Nurse Call System Market @ https://www.marketresearchfuture.com/sample_request/5631

Additionally, advances in healthcare IT and the early uptake of evolving IoT devices drive the market growth predominantly with hi-tech wired & wireless technology. Moreover, the rising awareness among demographics about healthcare and advantages of Nurse Call Systems substantiates the market growth. Also, Rapid increase in the global economy and urbanization boosts the growth of the market. The size of the nurse call system is exploding with the growing penetration of cloud & IoT (internet of things).

Furthermore, the availability of excellent coverage of network & connectivity, dropping prices of these devices, and negligible cost of scalability of communication provide a considerable impetus to the growth of the market. On the other hand, factors such as high installation & maintenance costs, concerns of privacy & information occurred due to the open networks, and lack of awareness for the benefits of these systems are impeding the market growth.

Impact of Covid-19 Outbreak on Nurse Call System Market

The Nurse Call System is an electrically operated system in hospitals and nursing homes and is placed beside the patient’s bed. It aids patients in health care settings to alert a nurse or any other health care staff member remotely if they need any help. Due to rising rate of COVID-19 patients around the globe there has been an increasing demand of nurse call systems. This rising demand can be attributed to increasing influx of patient in the hospitals which is creating a hindrance in the patient monitoring system of hospital. In this scenario, the nurse call system has been helping patients to call for assistance. According to Global Health Observatory, in 2017, about 50% of WHO Member States have around less than 3 nursing and midwifery personnel per 1,000 of population.

Various players in the nurse call system market are coming up with advanced and enhanced features of products in order to provide suitable solutions for COVID-19 pandemic. The use and expansion of digital health solutions can revolutionize the healthcare standards, and access services to promote health and well-being of people. Also, the government and private medical institutes are taking various initiatives to help the healthcare system in every possible way. In March 2020, World Health Organization (WHO) came up with global strategy on digital health 2020–2024, wherein it encourages and supports the health systems through the application of various digital health technologies in order achieve quality health services across the globe. The medical device companies are facing problem in manufacture, delivery and installation of devices in hospitals and clinics. The companies are have started client services through conference calling, video calling, and document collaboration, following the government’s norm of social distancing.

Market Research Future (MRFR) collected data on several factors including implications of COVID 19 Impact on Nurse Call System Market and demographic challenges, showed how it could move forward in the coming years.

Nurse Call System Market – Segmentations

The report is segmented into five dynamics:-

By Type: Nurse Call Buttons, Nurse Call Integrated Communication Systems, Nurse Call Mobile Systems, Nurse Call Intercoms, and others.

By Technology: Wired Systems and Wireless Systems.

By Application: Medical Emergency, Alarms, Work Flow Management, and others.

By End-User: Hospitals & Nursing Homes, Assisted Living Centers, Ambulatory Care Centers, and others.

By Regions: Americas, Europe, Asia Pacific, and the rest-of-the-world.

Global Nurse Call System Market – Regional Analysis

North America dominates the global nurse call system market. The largest market share attributes to the presence of several technology majors and prominent industry players in the region. Besides, early adoption of advanced technologies, high per capita healthcare expenditures and the availability of medical infrastructures act as driving forces for the regional market.

Additionally, increased R&D funding and aids provided by the governments to purchase futuristic nurse call systems drive the regional market growth. Well-developed economies such as the US and Canada accounts for considerable shares in the regional market. The North American nurse call system market is poised to retain its leading position in the global market throughout the forecast period.

Europe stands the second position in the global nurse call system market in terms of revenue and market size. The market growth is predominantly driven by the presence of well-developed healthcare industries and rising patient population & hospitalizations due to the increasing prevalence of myriads of chronic diseases in the region. The European nurse call system market is estimated to create a substantial revenue pocket over the assessment period.

Asia Pacific region has come up as a profitable market for nurse call systems globally. Factors such as the rising economic growth, rapidly developing healthcare facilities, and the increasing aging population in the region foster the market growth. APAC countries such as India, China, South Korea, and Japan are poised to remain at the forefront of the regional market. The APAC nurse call systems market is anticipated to grow rapidly over the review period.

Nurse Call System Market – Competitive Analysis

Highly competitive, the nurse call system market appears fragmented due to the presence of several well-established players. Industry players incorporate strategic initiatives such as mergers & acquisitions, collaborations, expansion, and product/technology launch to gain a larger competitive share in the market. They also make substantial investments to drive R&D required for the development of technology & products and to expand their global footprints.

Nurse Call System Market Major Players:

Players leading the nurse call system market manufacturers are Honeywell International Inc., Austco Communication Systems Pty Ltd., Hill-Rom Services Inc., CSINC, Ascom, Johnson Controls., AMETEK, Inc., West-Com Nurse Call System, Inc, STANLEY Healthcare, Azure Healthcare, Jeron Electronic Systems Inc., Cornell Communications, Vigil Health Solutions Inc., Systems Technologies, and BEC Integrated Solutions, LLC, among others.

Nurse Call System Industry/Innovation/Related News:

May 13, 2020 — The US FDA issued aEUA (Examination under anesthesia) for the Ascom teleCARE IP Nurse Call System and the Eko electrocardiogram (ECG) Low Ejection Fraction Tool (ELEFT). The FDA has been notified that more than 245 laboratories have begun testing under the policies set forth in its COVID-19 Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency Guidance.

May 13, 2020 — Ni Hsin Marketing SDN BHD (NHM – Malaysia), announced its collaboration with a Kuala Lumpur- based medical equipment manufacture – WTK Manufacturing SDN BHD (WTKM). The collaboration agreement is a distributorship agreement to market WTKM’s complete range of products, including protective fabric mask, personal protective equipment (PPE), and hand sanitizer domestically and internationally through Asia Pacific, Africa, Europe, United States, Middle East, and South Asia.

WTKM and WTKT are engaged in the development and manufacturing of a range of medical equipment, including a nurse call system, smart dispensary system, prefabricated operation theatre system, and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/upcoming-reports/nurse-call-system-market-5631